Ocular Therapeutix, Inc.
OCUL
OCUL: Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
moreShow OCUL Financials
Recent trades of OCUL by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by OCUL's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Methods of treating ocular diseases using polyalkylene glycol intracameral implants with polyactide travoprost particles Apr. 11, 2023
-
Patent Title: Punctal plug and bioadhesives Jan. 24, 2023
-
Patent Title: Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor Dec. 27, 2022
-
Patent Title: Punctal plug and bioadhesives Oct. 04, 2022
-
Patent Title: Ocular implant containing a tyrosine kinase inhibitor Sep. 13, 2022
-
Patent Title: Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine May. 17, 2022
-
Patent Title: Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine Apr. 05, 2022
Federal grants, loans, and purchases
Followers on OCUL's company Twitter account
Number of mentions of OCUL in WallStreetBets Daily Discussion
Recent insights relating to OCUL
Recent picks made for OCUL stock on CNBC
ETFs with the largest estimated holdings in OCUL
Flights by private jets registered to OCUL